Biological drugs targeting the immune response in the therapy of psoriasis

References

• BaumgarthNBevinsCL2007Skin deep but complexNature449551317873861
   PubMed Web of Science ®Google Scholar
• BoehnckeWHBrasieRABarkerJ2006Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensusJ Eur Acad Dermatol Venereol209889816922950
   PubMed Web of Science ®Google Scholar
• BongartzTSuttonAJSweetingMJ2006Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized trialsJAMA29522758516705109
   PubMed Web of Science ®Google Scholar
• Bruch-GerharzDSchnorrOSuschekC2003Arginase 1 over-expression in psoriasis. Limitation of inducible nitric oxide synthase activity as a molecular mechanism for keratinocyte hyperproliferationAm J Pathol1622031112507903
   PubMed Web of Science ®Google Scholar
• CassanoNLoconsoleFGalluccioA2006Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: results of a pilot experience (power study)Int J Immunopathol Pharmacol198237
   Web of Science ®Google Scholar
• ChaudhariURomanoPMulcahyLD2001Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trialLancet927118424711410193
   PubMedGoogle Scholar
• DziadzioMSmithR2007Meta-analysis is no substitute for a comprehensive national registryClin Rheumatol261134517115099
   PubMed Web of Science ®Google Scholar
• DubertretLSterryWBosJD2006Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trialBr J Dermatol1551708116792770
   PubMed Web of Science ®Google Scholar
• GirolomoniGPastoreSAlbanesiC2002Targeting tumor necrosis factor-α as a potential therapy in skin inflammatory skin diseasesCurr Opin Investig Drugs315905
   PubMedGoogle Scholar
• GisondiPGubinelliECocurocciaB2004Targeting tumor necrosis factor-α in the therapy of psoriasisCurr Drug Targets Inflamm Allergy31758315180471
   PubMedGoogle Scholar
• GordonKBPappKAHamiltonTK2003Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialJAMA2903133514679277
   PubMed Web of Science ®Google Scholar
• GordonKBWestDT2001Biologic therapy in psoriasisWolvertonSComprehensive dermatologic drug therapyPhiladelphia, PAWB Saunders Co92842
   Google Scholar
• GottliebABMathesonRTLoweN2003aA randomized trial of etanercept as monotherapy for psoriasisArch Dermatol13916273214676082
   PubMed Web of Science ®Google Scholar
• GottliebABChaudhariUMulcahyLD2003bInfliximab mono-therapy provides rapid and sustained benefit for plaque-type psoriasisJ Am Acad Dermatol488293512789171
   PubMed Web of Science ®Google Scholar
• GottliebABEvansRLiS2004Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized double-blind, placebo-controlled trialJ Am Acad Dermatol515344215389187
   PubMed Web of Science ®Google Scholar
• GottliebABHamiltonTCaroI2006Efalizumab Study Group. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasisJ Am Acad Dermatol54515463
   Google Scholar
• GriffithsCEMBarkerJNWN2007Pathogenesis and clinical features of psoriasisLancet3702637117658397
   PubMed Web of Science ®Google Scholar
• HankinCSFeldmanSRSzczotkaA2005A cost comparison of treatments for moderate to severe psoriasisDrug Ben Trends1720014
   Google Scholar
• HeenenMLaporteMNoelJC1998Methotrexate induces apoptotic cell death in human keratinocytesArch Dermatol Res29024059681674
   PubMed Web of Science ®Google Scholar
• HochbergMCLebwohlMGPlevySE2005The benefit/risk profile of TNF-blocking agents: findings of a consensus panelSemin Arthritis Rheum348193615942917
   PubMed Web of Science ®Google Scholar
• HoggNLaschingerMGilesK2003T cell integrins: more than just sticking pointsJ Cell Sci116469570514600256
   PubMed Web of Science ®Google Scholar
• KruegerGElewskiBPappK2006Patients with psoriasis respond to continuous open-label Etanercept treatment after initial incomplete response in randomized, placebo controlled trialJ Am Acad Dermatol54S112916488321
   PubMed Web of Science ®Google Scholar
• LandeRGregorioJFacchinettiV2007Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptideNature449564917873860
   PubMed Web of Science ®Google Scholar
• LangleyRGCareyWPRafalES2005Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experienceClin Ther2713172816291408
   PubMed Web of Science ®Google Scholar
• LebwohlMTyringSKHamiltonTK2003A novel targeted T-cell modulator, efalizumab, for plaque psoriasisN Engl J Med34920041314627785
   PubMed Web of Science ®Google Scholar
• LeonardiCLPowersJLMathesonRT2003Etanercept as mono-therapy in patients with psoriasisN Engl J Med34920142214627786
   PubMed Web of Science ®Google Scholar
• LewisTGTuchindaHWLimHKW2005Life-threatening pustolar and erythrodermic psoriasis responding to infliximabJ Drugs Dermatol5546816774108
   PubMedGoogle Scholar
• LiuYKruegerJGBowcockAM2007Psoriasis: genetic associations and immune system changesGenes Immun811217093502
   PubMed Web of Science ®Google Scholar
• LocksleyRMKilleenNLenardoMJ2001The TNF and TNF receptor superfamilies: integrating mammalian biologyCell10448750111239407
   PubMed Web of Science ®Google Scholar
• MaglioccoMAGottliebAB2004Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of three casesJ Am Acad Dermatol51580415389194
   PubMed Web of Science ®Google Scholar
• MenterAGordonKCareyW2005Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasisArch Dermatol14131815655139
   PubMed Web of Science ®Google Scholar
• MenterAFeldmanSRWeinsteinGD2007A randomized comparison of continuous vs. intermittent infliximab mainenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasisJ Am Acad Dermatol56314417097378
   PubMed Web of Science ®Google Scholar
• MenterAGriffithsCE2007Current and future management of psoriasisLancet3702728417658398
   PubMed Web of Science ®Google Scholar
• MuellerWHerrmannB1979Cyclosporin A for psoriasisN Engl J Med301555460314
   PubMed Web of Science ®Google Scholar
• NelsonAAPearceDJFleischerAB2008Cost-effectiveness of biological treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment periodJ Am Acad Dermatol58125517996329
   PubMed Web of Science ®Google Scholar
• OngPYOhtakeTBrandtC2002Endogenous antimicrobial peptides and skin infections in atopic dermatitisN Engl J Med34711516012374875
   PubMed Web of Science ®Google Scholar
• PappKATyringSLahfaM2005A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionBr J Dermatol15213041215948997
   PubMed Web of Science ®Google Scholar
• PappKA2006The long-term efficacy and safety of new biological therapies for psoriasisArch Dermatol Res29871516691429
   PubMed Web of Science ®Google Scholar
• PasparakisMCurtoisGHafnerM2002TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2Nature417861612075355
   PubMed Web of Science ®Google Scholar
• PastoreSMasciaFMarianiV2006Keratinocytes in skin inflammationExpert Rev Dermatol127991
   Google Scholar
• PincelliCHenningerECasset-SemanazF2006The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumabArch Dermatol Res2983293817021768
   PubMed Web of Science ®Google Scholar
• ReichKNestleFOPappK2005EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialLancet36613677416226614
   PubMed Web of Science ®Google Scholar
• RobinsonMRKormanBDKormanNJ2007Combination immunosuppressive therapiesArch Dermatol1431053717709665
   PubMedGoogle Scholar
• RokhsarCRabhanNCohenSR2006Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infectionJ Am Acad Dermatol54361216443079
   PubMed Web of Science ®Google Scholar
• SchonMPLudwigRJ2005Lymphocyte trafficking to inflamed skin. Molecular mechanisms and implications for therapeutic target moleculesExpert Opin Ther Targets92254315934912
   PubMed Web of Science ®Google Scholar
• SchwartzPMBarnettSKAttillasoyES1992Methotrexate induces differentiation of human keratinocytesProc Natl Acad Sci U S A8959481731329
   PubMed Web of Science ®Google Scholar
• ShikiarRWillianMKOkunMM2006The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II studyHealth Qual Life Outcomes47117005043
   PubMed Web of Science ®Google Scholar
• SkomsvollJFWalleniusMKoksvikHS2007Drug Insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactationNat Clin Pract Rheumatol31566417334338
   PubMedGoogle Scholar
• SmithCHAnsteyAVBarkerJNWN2005British Association of Dermatology Guidelines for the use of biological interventions in psoriasis 2005Br J Dermatol1534869716120132
   PubMed Web of Science ®Google Scholar
• SterryWStinglGLangleyRG2006Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trialJ Dtsch Dermatol Ges49475617081270
   PubMedGoogle Scholar
• TraversJB2000Novel immunomodulators for topical skin disease therapyExpert Opin Invest Drugs952942
   PubMed Web of Science ®Google Scholar
• ValdimarssonH2007The genetic basis of psoriasisClin Dermatol25563718021893
   PubMed Web of Science ®Google Scholar
• WahieSAlexandruffAReynoldsNJ2006Psoriasis occurring after myeloablative therapy and autologous stem cell transplantationBr J Dermatol154194516729392
   PubMed Web of Science ®Google Scholar
• WeinbergJM2006A review of the safety of the tumor necrosis inhibitors infliximab, etanercept, and adalimumabWeinbergJMBuchholzRTNF-alpha inhibitorsBaselBirkhäuser11527
   Google Scholar
• ZeichnerJALebwohlM2007Potential complications associated with the use of biologic agents for psoriasisDermatol Clin252071317430757
   PubMed Web of Science ®Google Scholar